OCS | Ticker Profile - Titan Protect

OCS

Oculis Holding AG

Healthcare · Biotechnology · NGM

$11.21

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$1.8B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-14.14

Based on estimated future earnings — lower means cheaper

Rev Growth

-26.7%

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

-52.7%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$49.16

+339% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 10 analysts covering this stock

About Oculis Holding AG

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.

https://oculis.com

Country: Switzerland Employees: 60 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

1.263

Excellent risk-adjusted returns

Kelly Fraction

0.0792

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

1.558

Returns exceed worst-case losses — strong risk profile

Annual Return

58.1%

Historical annualised return based on price data

Max Drawdown

-37.3%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$34.48

67% below the year high

52W Low

$16.00

-30% above the year low

Avg Volume

388,029

Average daily shares traded — higher means easier to buy and sell

Short Ratio

1.1

Days it would take all short sellers to cover — higher means more crowded

Short % Float

1.0%

Low short interest — limited bearish positioning

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-2.16

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

1.14

Meaningful debt load — monitor closely

Current Ratio

5.18

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

5.09

Like current ratio but excludes inventory — stricter test

Gross Margin

0.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-10,396.2%

Profit from core operations before interest and tax

Free Cash Flow

N/A

Negative — the business is spending more than it generates

Revenue (TTM)

$1M

Total revenue over the last 12 months

Net Income

$-94,596,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$74.96

Target Median

$49.16

Target Low

$41.95

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go